The hippo signaling pathway in pancreatic cancer

Forskningsoutput: TidskriftsbidragÖversiktsartikel

Abstract

Hippo signaling is a key regulator of organ size, tissue hemostasis and regeneration. Dysregulation of the Hippo pathway has been recognized in a variety of human cancers, including pancreatic cancer. YES-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are the two major downstream effectors of the Hippo pathway. YAP and TAZ have been found to promote pancreatic tumor development and progression, even in the absence of mutant Kirsten RAS (KRAS). Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Skåne University Hospital
  • Wenzhou Medical University
  • Lund University
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
  • Cellbiologi

Nyckelord

Originalspråkengelska
Sidor (från-till)3317-3321
Antal sidor5
TidskriftAnticancer research
Volym39
Utgåva nummer7
StatusPublished - 2019 jul
PublikationskategoriForskning
Peer review utfördJa